Related Experiment Videos
Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter
M Boccadoro1, P Omedè, R Frieri
1Dipartimento di Medicina e Oncologia Sperimentale, Cattedra di Ematologia, Università di Torino, Italia.
Acta Haematologica
|January 1, 1989
Summary
Serum beta-2-microglobulin (beta 2M) is not a reliable indicator for detecting remission or relapse in multiple myeloma (MM). M-component determination is a more dependable method for monitoring tumor variations in MM patients.
Area of Science:
- Oncology
- Hematology
- Clinical Chemistry
Background:
- Serum beta-2-microglobulin (beta 2M) is recognized as a significant prognostic factor in multiple myeloma (MM).
- The utility of beta 2M in monitoring disease status, specifically remission and relapse, requires further investigation.
Purpose of the Study:
- To evaluate the reliability of serum beta-2-microglobulin (beta 2M) in detecting remission and relapse in individual multiple myeloma (MM) patients.
- To compare the effectiveness of beta 2M with M-component determination for monitoring tumor variations.
Main Methods:
- Correlation analysis between serum beta 2M and M-component levels.
- Monthly monitoring of 21 consecutive MM patients with normal renal function from diagnosis.
- Assessment of statistical significance in parameter correlations.
Main Results:
- A statistically significant correlation between beta 2M and M-component was observed in only 52.4% of patients.
- Lack of correlation was attributed to low initial beta 2M production or independent fluctuations.
- Serum beta 2M was found to be less reliable than M-component for detecting tumor variations.
Conclusions:
- Serum beta-2-microglobulin (beta 2M) is not a consistently reliable marker for tracking remission and relapse in multiple myeloma (MM).
- M-component determination offers a more dependable method for monitoring disease progression and treatment response in MM.